Cost-effectiveness of narlaprevir in the chronic hepatitis C (genotype 1) therapy in treatment-naïve patients and relapsers

In the treatment of chronic hepatitis C (CHC) protease inhibitors (PI) are actively used. The aim of this analysis was to evaluate the cost-effectiveness of narlaprevir and simeprevir in the CHC (genotype 1) therapy in treatment-naïve patients and relapsers.Material and methods. Analysis of the cost...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: D. A. Gusev, A. V. Rudakova, A. N. Uskov, L. N. Konovalova, Yu. V. Lobzin
Formato: Artigo
Idioma:Russo
Publicado em: Journal Infectology 2016-11-01
Colecção:Žurnal Infektologii
Assuntos:
chronic hepatitis c
naive patients
relapse
simeprevir
narlaprevir
cost-effectiveness
Acesso em linha:https://journal.niidi.ru/jofin/article/view/514
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados